Background {#Sec1}
==========

The molecular analysis of human cancer cells has revealed a startling amount of genetic and epigenetic heterogeneity. In recent years, forward genetic screens have taken place in mice using DNA transposons, primarily Sleeping Beauty (SB) \[[@CR1]\]. The SB-based approach has been successfully employed to induce many different forms of cancer such as brain tumors, sarcomas, hematopoietic malignancies, and carcinomas \[[@CR2], [@CR3]\] via insertional mutagenesis. A large number of of loci recurrently mutated by insertion of SB transposons called common insertion sites (CIS) have been identified \[[@CR4]\]. The general impression from these studies is one of tremendous genetic complexity.

Recent large-scale analyses of human cancer genomes mirrors these results in general. Most types of human cancer harbor a small number of genes that are altered in a high percentage of cases, so called "mountains", and a large number of genes altered in a low percentage of cases, so called "hills". In addition, two patients diagnosed with the same type of cancer often show distinct genetic alternations, however, the disrupted pathways tend to be similar among patients \[[@CR5]\].

Conventional pathway analysis approaches usually obtain gene-based scores by summarizing data across tumor cases, then calculating pathway statistics using the scores of the genes in the pathway. However, these approaches could potentially lose information regarding whether multiple mutations in a pathway are from a single patient or multiple cases with a single mutation at various genes in the pathway. In contrast, case-oriented gene set analysis (CO-GSEA) can consider the two situations differently and hence can incorporate heterogeneity of each tumor case into the analysis. This approach provides a case-based score for each pathway and further enhances the study of correlation of mutation events between pathways, as well as between genes and pathways. It has recently been applied to the analysis of human tumors \[[@CR6]\].

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of death due to cancer, with over a 98 % case-fatality rate. The crucial molecular events, required for progression from a pre-invasive and non-life threatening state to an invasive and metastatic lethal condition, are not well-understood. We previously reported the results of a SB transposon-based forward genetic screen for drivers of PDA in mice expressing the Kras^G12D^ oncogene in epithelial cells of the pancreas \[[@CR7]\]. Our screen revealed new candidate genes for PDA and confirmed the importance of many genes and pathways previously implicated in human PDA. The most commonly mutated gene was the X chromosome-linked deubiquitinase *Usp9x*, which was inactivated in over 50 % of the tumors. In addition, several hundred candidate PDA genes were identified as CIS in this screen.

In this paper, we report analyses intended to determine whether a core group biological processes or pathways are populated by genes from CIS. We applied a less stringent criterion to consider CIS associated genes that mutated both at high frequencies (mountains) and at lower frequencies (hills). Secondly, we determined whether non-random associations between alteration of genes in certain pathways or biological pathways exist by analysis of CIS from individual tumors.

Results and discussion {#Sec2}
======================

Certain pathways are enriched in CIS-associated genes {#Sec3}
-----------------------------------------------------

We collected insertional mutatgenesis data of tumor samples from 146 *Kras*^*LSL-G12D*^*; Pdx1-cre; T2/Onc; Rosa26-LSL-SB13* mice. To determine whether a core group of pathways were enriched with CIS-associated genes than reported previously \[[@CR7]\], we analyszed 968 CIS with uncorrected *p* value \<10^−4^ from TapDance. Among these, 239 genes were mapped an grouped into 281 KEGG curated pathways categories. After excluding pathways with less than 6 genes, 272 KEGG pathways remain in the following analysis.

Using the CO-GSEA described in the Method Section, we found 95 KEGG pathways that are enriched with CIS-associated genes with permutated *p* value \<10^−7^ listed in Table [1](#Tab1){ref-type="table"} (more details about the disrupted genes in each pathway can be found in Additional file [1](#MOESM1){ref-type="media"}). In Table [1](#Tab1){ref-type="table"}, "\# of genes" records the number of genes defined in the pathway from KEGG; "\# of CIS" (third column) reports the number of CIS genes in the pathway; and "\# of mutated cases" (fourth column) records the number of cases that the pathway was disrupted. A histogram of the sizes of each of the KEGG pathways is shown in Additional file [2](#MOESM2){ref-type="media"}. In Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, we plotted the KEGG diagrams of two pathways that are enriched CIS-associated genes. Fig. 1Frequently mutated genes in ubiquitin mediated proteolysis pathway. Darker red color indicates higher mutation frequencies in miceFig. 2Frequently mutated genes in ErbB signaling pathway. Darker color indicates higher mutation frequencies in miceTable 1Pathways that are enriched with CIS-associated genes (permuted *p* value \<10^−7^)KEGG idPathway name\# of genes\# of CIS\# of mutated casesCellular Processes14110Cell cycle126910124530Tight junction1361012734810Regulation of actin cytoskeleton2171312144510Focal adhesion2071312354540Gap junction8736764520Adherens junction7411122Human Diseases75164Influenza A1701111785034Alcoholism19958595169Epstein-Barr virus infection21217120105203Viral carcinogenesis22914116115160Hepatitis C136797125010Alzheimer's disease17312121135016Huntington's disease18214125145200Pathways in cancer32323134155211Renal cell carcinoma67684165206MicroRNAs in cancer27010108175152Tuberculosis17611114185166HTLV-I infection27711106195100Bacterial invasion of epithelial cells777103205412Arrhythmogenic right ventricular cardiomyopathy (ARVC)74796215202Transcriptional misregulation in cancer17812121225133Pertussis74684235142Chagas disease (American trypanosomiasis)103787245161Hepatitis B14510107255205Proteoglycans in cancer22611115265214Glioma65695275216Thyroid cancer29366285210Colorectal cancer648105295212Pancreatic cancer66674305213Endometrial cancer528111315215Prostate cancer8910117325218Melanoma71486335219Bladder cancer38246345220Chronic myeloid leukemia73995355221Acute myeloid leukemia57682365223Non-small cell lung cancer56577375222Small cell lung cancer85795385217Basal cell carcinoma55365Environmental Information Processing394151PI3K-Akt signaling pathway35122130404390Hippo signaling pathway15414123414066HIF-1 signaling pathway111791424012ErbB signaling pathway877100434014Ras signaling pathway22813119444310Wnt signaling pathway14316126454350TGF-beta signaling pathway8211119464010MAPK signaling pathway25314118474015Rap1 signaling pathway21614134484370VEGF signaling pathway60468494340Hedgehog signaling pathway49361504330Notch signaling pathway49468514070Phosphatidylinositol signaling system81478524068FoxO signaling pathway1357101534150mTOR signaling pathway61486Metabolism544141Protein processing in endoplasmic reticulum169811155670One carbon pool by folate19245563015mRNA surveillance pathway96895574120Ubiquitin mediated proteolysis139141185800250Alanine, aspartate and glutamate metabolism34253593020RNA polymerase2925060510N-Glycan biosynthesis50369613018RNA degradation7758362310Lysine degradation5169563512Mucin type O-Glycan biosynthesis2824664900Terpenoid backbone biosynthesis2125465563Glycosylphosphatidylinositol(GPI)-anchor biosynthesis25246664122Sulfur relay system10359674062Chemokine signaling pathway19613124684722Neurotrophin signaling pathway12312118694670Leukocyte transendothelial migration1219106704728Dopaminergic synapse1338105714270Vascular smooth muscle contraction1378104724713Circadian entrainment98593734723Retrograde endocannabinoid signaling103488744724Glutamatergic synapse114593754725Cholinergic synapse113593764726Serotonergic synapse133594774910Insulin signaling pathway142895784650Natural killer cell mediated cytotoxicity146573794917Prolactin signaling pathway74798804611Platelet activation1319111814912GnRH signaling pathway89580824914Progesterone-mediated oocyte maturation87468834915Estrogen signaling pathway98692844916Melanogenesis1009111854921Oxytocin signaling pathway1589108864360Axon guidance12910117874919Thyroid hormone signaling pathway11811114884960Aldosterone-regulated sodium reabsorption40249894720Long-term potentiation66691904660T cell receptor signaling pathway1059113914662B cell receptor signaling pathway73691924730Long-term depression61367934664Fc epsilon RI signaling pathway70468944666Fc gamma R-mediated phagocytosis88686954320Dorso-ventral axis formation22260

The genetic screen was designed to discover genes that when altered would cause acceleration of PDA in pancreatic ductal epithelial cells expressing an activated form of the Kras oncogene, *Kras*^*G12D*^. As such it was not surprising that KEGG pathways with the strongest statistical support for CIS associated gene enrichment were many cancer associated pathways. As expected, we found some of the same pathways previously reported and which were expected \[[@CR7], [@CR8]\]. An informal prior analysis \[[@CR7]\] suggested that *TGF* *β* signaling was enriched in CIS-associated genes and indeed we found that this KEGG pathway is enriched. Similarly, *Rb1/p16Inka4a* pathway was suggested to be recurrently altered by CIS-associated genes \[[@CR7]\]. Indeed, we found that the KEGG pathway *CELL CYCLE* was enriched in CIS-associated genes. Many other cancer-associated pathways were enriched in CIS-associated genes including the *RAS*, *PI3K-AKT*, *HIPPO*, *VEGF*, *HEDGEHOG*, *MAPK*, *FOXO1*, and *MTOR* pathways. Moreover, the human disease KEGG pathway *PANCREATIC CANCER* and several other human cancer pathways were enriched in CIS-associated genes.

In addition to these expected KEGG pathways, many involving metabolism have not been strongly linked to pancreatic cancer development or cancer development in general. However, recent studies revealed evidence of metabolic reprogramming to sustain tumor survival in *KRAS*-mutated PDA tumors \[[@CR9]\]. For example, KRAS-dependent tumor cells compensated the energy loss through increasing glycolysis, amino acid and lipid biosynthesis \[[@CR10]\]. In particular, *TERPENOID BIOSYNTHESIS*, *LYSINE DEGRADATION* and the *SULFUR RELAY SYSTEM* are significantly altered in the SB-accelerated tumor models. To date KRAS remains a poorly druggable target, hence, targeting the downstream metabolic regulation could be effective alternatives in inhibiting tumor growth.

Several organismal systems KEGG pathways were also enriched in CIS-associated genes despite not being strongly linked to pancreatic cancer development. These include *OXYTOCIN SIGNALING*, *CHOLINERGIC SYNAPSE*, and *MELANOGENESIS*. Our recent work helped show that the *AXON GUIDANCE* pathway is enriched for CIS-associated genes, a result which led to the discovery that these genes and the pathways they participate in are altered in human PDA \[[@CR8]\]. This result was reproduced in this current analysis. Thus, it is clear that the broadened definition of CIS allows for the identification of many known and novel candidate cancer pathways. These data suggest many new hypotheses to be tested in PDA development.

Analysis of individual tumor reveals significant co-altered pathways {#Sec4}
--------------------------------------------------------------------

We and others have published results of SB screens in which we found that individual CIS tended to be co-mutated by transposon insertion more than expected by chance (e.g. \[[@CR11]\]). We wondered whether an analysis of individual tumors would reveal that specific pathways would be co-altered in this same manner. Figure [3](#Fig3){ref-type="fig"} shows a heat map of adjusted correlation between pair of pathways, which are co-altered by transposon insertions within/near genes in those pathways. We observed that there are two major clusters of strongly co-altered pathways. Within these clusters certain specific pathways show strong associations, being altered by transposon insertion in the same tumors more often than would be expected by chance. These data provide the basis for developing specific hypotheses about pathways that interact to cause cancer. Thus, alterations of one pathway may allow the other pathway to exert its full oncogenic effects. Fig. 3Heat map of correlation between pair of pathways. Legend indicates strength of correlation coefficient (*red*: high correlation; *black*: weak correlation). **a** Heat map of correlation between all pairs of pathways. **b** Zoom in of block 1 shown in panel **a**. **c** Zoom in of block 2 shown in panel **a**. Pathway names from left to right (bottom to top): 1: Ubiquitin mediated proteolysis, 2: One carbon pool by folate, 3: Wnt signaling pathway, 4: Cell cycle, 5: Hippo signaling pathway, 6: Protein processing in endoplasmic reticulum, 7: MAPK signaling pathway, 8: Lysine degradation, 9: RNA polymerase, 10: N-Glycan biosynthesis, 11: mRNA surveillance pathway, 12: Hedgehog signaling pathway, 13: Dopaminergic synapse, 14: GPI-anchor, 15: RNA degradation, 16: Terpenoid backbone biosynthesis, 17: Mucin type O-Glycan biosynthesis, 18: Rap1 signaling pathway, 19: Adherens junction, 20: Leukocyte transendothelial migration, 21: TGF-beta signaling pathway, 22: Axon guidance, 23: MicroRNAs in cancer, 24: Tight junction, 25: PI3K-Akt signaling pathway, 26: Ras signaling pathway, 27: Chemokine signaling pathway, 28: Serotonergic synapse, 29: Glutamatergic synapse, 30: Cholinergic synapse, 31: Retrograde endocannabinoid signaling, 32: Circadian entrainment, 33: Sulfur relay system, 34: Notch signaling pathway, 35: Alanine, aspartate and glutamate metabolism, 36: Aldosterone-regulated sodium reabsorption, 37: Natural killer cell mediated cytotoxicity, 38: VEGF signaling pathway, 39: Fc epsilon RI signaling pathway, 40: Gap junction, 41: Melanogenesis, 42: FoxO signaling pathway, 43: HIF-1 signaling pathway, 44: Fc gamma R-mediated phagocytosis, 45: Estrogen signaling pathway, 46: Platelet activation, 47: Oxytocin signaling pathway, 48: Vascular smooth muscle contraction, 49: PIP, 50: mTOR signaling pathway, 51: Focal adhesion, 52: Regulation of actin cytoskeleton, 53: Insulin signaling pathway, 54: Thyroid hormone signaling pathway, 55: ErbB signaling pathway, 56: T cell receptor signaling pathway, 57: Neurotrophin signaling pathway, 58: B cell receptor signaling pathway, 59: Prolactin signaling pathway

A careful analysis of some of the associations reveals pairs of pathways that might be predicted to interact based on what is known about their functions and regulation already. For example, block 1, labeled in Fig. [3](#Fig3){ref-type="fig"}, contains strong associations between the ubiquitin processing pathway and several pathways including *ErbB*, *Insulin* and *mTOR* signaling. It is known that cell signaling pathways that transmit signals from the extracellular space into the cell cytoplasm and nucleus are regulated by the abundance and stability of certain proteins. In many cases, the stability of these proteins is regulated by ubiquitination and degradation by the proteosome. Well known examples, include *NF* *κB* and *Wnt/ β-catenin* signaling pathways. Work shows that members of the ErbB family of receptors are downregulated by ubiquitination involving the E3 ubiquitin ligase Cbl \[[@CR12]\]. Ubiquitination also regulates *Akt-mTOR* signaling in multiple myeloma \[[@CR13]\] and *Akt-mTOR* is activated by *insulinsignaling* \[[@CR14]\].

Block 2, labeled in Fig. [3](#Fig3){ref-type="fig"} contains several other intriguing pathway-pathway associations. For example, we see a strong association between cell cycle control and miRNAs known to be involved in cancer. Indeed, there are several well studied examples of miRNAs that regulate the mRNA transcripts of cell cycle regulators such as MYC \[[@CR15]\], RB1 \[[@CR16]\] and CCND1 \[[@CR17]\]. Also in block 2, we see evidence for *TGF β* pathway and *MAPK* pathway co-dysregulation. Abundant evidence for crosstalk between these pathways has been published \[[@CR18], [@CR19]\]. Thus, it is entirely plausible that co-alteration between these pathways is specifically selected for during PDA progression. Specific hypotheses can, or have been, tested in the laboratory. For example, MAPK activation, via expression of the Kras^G12D^ oncogene, cooperates strongly with Smad4 inactivation, which alters/inactivates *TGF β* signaling, in a mouse model of PDA \[[@CR20]\]. This functionally confirms the observation from the analyses done here. We can thus predict, that many other pathway-pathway associations observed in Fig. [3](#Fig3){ref-type="fig"} can be functionally validated. More speculative, but of tremendous therapeutic significance, is the idea that targeting one pathway of a pathway-pathway pair observed in Fig. [3](#Fig3){ref-type="fig"} would alter the ability of the second pathway to exert its oncogenic effects. Indeed, co-targeting both of such pairs of altered pathways may be the most effective way to treat individual cases of PDA. These ideas wait functional testing in the laboratory using model systems.

Association of CIS-associated genes and enriched pathways {#Sec5}
---------------------------------------------------------

Several of the most commonly altered genes in the PDA screen (i.e. the top ranked CIS-associated genes) have little published functional data. We speculate that by finding which pathways they most often interact with, something could be learned about their function in general and in PDA development. The associations between the top ranked CIS and enriched pathways are shown in Fig. [4](#Fig4){ref-type="fig"}. In Fig. [4](#Fig4){ref-type="fig"}, several CIS-associated genes such as *Stag2*, *Arhgap5*, *Usp9x*, *Magi1*, *Arid1a* have few connections to enriched pathways then other CIS-associated genes. In Additional file [3](#MOESM3){ref-type="media"}, we listed these connections and corresponding estimates from regression model, *p* values and FDR. For example, in Additional file [1](#MOESM1){ref-type="media"}, *Usp9x* is associated with *PI3K-AKT signaling* pathway, *DOPAMINERGICSYNAPSE*, *HIPPO signaling*, and *TIGHT JUNCTION* pathways. Thus, it seems likely that *Usp9x* mutation or down regulation has to cooperate with alterations in these other pathways in order for PDA to develop. The CIS-associated genes that also demonstrated association with the these *Usp9x*-associated pathways are *Gsk3b*, *Ctnna1*, *Mll5*, *Pten*, *Arfip1*, *Magil*. Fig. 4Associations between CIS and enriched pathways. Red nodes represent CIS associated genes, and blue nodes indicate pathways. Abbreviations: miRNAs: MicroRNAs in cancer, GPI: Glycosylphosphatidylinositol-anchor biosynthesis, T.J.: Tight junction, Hedgehog: Hedgehog signaling pathway, PIP: Phosphatidylinositol signaling system, B cell: B cell receptor signaling pathway, Leuk. M.: Leukocyte transendothelial migration, DA: Dopaminergic synapse, Axon: Axon guidance, Ubiquitin: Ubiquitin mediated proteolysis, F.A: Focal adhesion, M.G.: Melanogenesis, Lysine D.: Lysine degradation, Protein: Protein processing in endoplasmic reticulum, T cell: T cell receptor signaling pathway, T.H.: Thyroid hormone signaling pathway, N.T: Neurotrophin signaling pathway, A.J.: Adherens junction, Actin: Regulation of actin cytoskeleton, Ck: Chemokine signaling pathway

Conclusion {#Sec6}
==========

In this work, we demonstrate the non-random enrichment of CIS-associated genes from a transposon-based screen for PDA into certain KEGG signaling pathways, disease states and biological processes.

Methods {#Sec7}
=======

To assess whether a pathway harbors more CIS-associated genes than expected by chance, we use CO-GSEA approach. For each tumor sample, we considered a pathway is altered (coded: 1) if at least 1 gene in the pathway was mutated; coded zero if it's not. A score for each pathway was calculated to be the number of tumors in which the pathway is altered. We assessed whether the score of a pathway was statistically significant through random permutation. For example, if a mouse tumor contains 100 mutations, we randomly assigned the 100 mutations to 100 different genes. A score for each pathway can be obtained by counting the number of altered tumor samples after the permutation. We repeated the permutation 10^7^ times to obtain the distribution of score under the null for each pathway and calculated a *p* value based on the permuted null distribution. A similar approach was also applied in mutation analysis of human tumor samples in \[[@CR6]\].

The ability to detect a significant pathway using the CO-GSEA approach depends on the background mutation rate and the size of the pathway under consideration. The relationship between the number of total cases, and the expected score of a given pathway under random permutation can be described as: $\documentclass[12pt]{minimal}
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                \begin{document}$N- \Sigma _{i=1}^{N}\tiny {\frac {\left (\! \begin {array}{c} G-n_{i} \\ P_{s} \end {array} \!\right)} {\left (\! \begin {array}{c} G\\ P_{s} \end {array} \!\right)}}$\end{document}$, where *N* is the total number of cases; G is the number of genes considered in the pathway analysis; *n*~*i*~ is the number of events in sample *i* and *P*~*s*~ is the number of genes in the pathway \[[@CR6]\].

Analysis of co-altered pathways {#Sec8}
-------------------------------

To investigate whether a pair of pathways was co-altered in a significant manner, we remove the CIS-associated genes that are present in both pathways, and for each sample, we calculated the mutation frequency in each pathway using the remaining non-overlapping CIS as: $\documentclass[12pt]{minimal}
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                \begin{document}$\frac {\text {\# of mutations in sample } i\text { in the pathway}}{\text {\# of non-overlapping CIS in the pathway}}$\end{document}$. For each pair of pathways, Pearson correlations were calculated to present the correlation between pathways characterized by non-overlapping CIS using the mutation counts.

Association between top CIS-associated genes and enriched pathways {#Sec9}
------------------------------------------------------------------

Among the top 20 CIS-associated genes previously reported \[[@CR7]\], 12 of them listed do not map to any KEGG pathways. We conducted association analysis between the top 20 CIS-associated genes and the enriched KEGG pathway using quasi-Poisson regression models with over-dispersion. For each CIS-associated gene, we examined whether mutation status of the CIS-associated gene (code 1 if mutated; 0 otherwise) is associated with higher mutation counts (the number of altered CIS-associated genes) for a pathway under consideration. We reported the CIS and pathways associations with FDR \< 0.001.
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